<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-101669</identifier>
<setSpec>0212-6567</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Use of prescription drugs in Spain and Europe</dc:title>
<dc:description xml:lang="en">Objective: To compare the Spanish prescription drug consumption with that of European countries. Design: A review of the literature and data sources for prescription drug consumption. Setting: European countries; last three decades. Participants: Included therapeutic groups where the available information allowed a comparison of the consumption in Spain with that of other European countries. Measurements: Studies, reports, or data sources were included in which the consumption was expressed in DHD (DDD/1000 inhabitants per day). Results: It was possible to compare 18 therapeutic groups: drugs for peptic ulcer (A02B), glucose lowering drugs (A10), antithrombotic agents vitamin K antagonists (B01AA), antihypertensives (C02), diuretics (C03), peripheral vasodilators (C04), beta-blocking agents (C07), calcium channel blockers (C08), agents acting on the renin-angiotensin system (C09), lipid-lowering drugs (C10), antibacterials for systemic use (J01), antiinflammatory &amp; antirheumatic products non-steroids (M01A), opioid analgesics (N02A), antipsychotics (N05A); anxiolytics (N05B), hypnotics &amp; sedatives (N05C), antidepressants (N06A) and drugs for obstructive airway diseases (R03). With regard to the European average (100), the Spanish consumption of these therapeutic groups was: N02A, 37; C07, 40; B01AA, 41; C03, 70; N05C, 72; C10, 75; C08, 76; N05A, 77; TH01, 97; N06A, 98; C09, 104; M01A, 101; R03, 101; C02, 107; A10, 114; N05B, 137; A02B, 150 and C04, 234. Conclusions: The Spanish consumption of most of the therapeutic groups was very close to the average of the group of the countries where it was possible to compare it, or clearly below average, with the exception of the consumption of drugs for peptic ulcer, anxiolytics and peripheral vasodilators, which considerably exceeded the average of the group(AU)</dc:description>
<dc:creator>Simó Miñana, Juan</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Objetivo: Comparar el consumo español de medicamentos con el de los países europeos. Diseño: Revisión bibliográfica y de fuentes de datos de consumo de medicamentos. Emplazamiento: Países europeos; últimas 3 décadas. Participantes: Se incluyen aquellos grupos terapéuticos cuya información detectada permite comparar su consumo en España con el de otros países europeos. Mediciones: Se incluyen aquellos estudios, informes y fuentes de datos cuyos resultados de consumo se expresen en DHD (dosis diarias definidas/1.000 habitantes/día). Resultados: La información detectada permitió comparar 18 grupos terapéuticos: antiulcerosos (A02B), antidiabéticos (A10), antitrombóticos antivitamina K (B01AA), antihipertensivos (C02), diuréticos (C03), vasodilatadores periféricos (C04), betabloqueantes (C07), bloqueantes de los canales del calcio (C08), agentes activos sobre el sistema renina-angiotensina (C09), hipolipidemiantes (C10), antibióticos (J01), antiinflamatorios y antirreumáticos no esteroideos (M01A), analgésicos opioides (N02A), antipsicóticos (N05A), ansiolíticos (N05B), hipnóticos y sedantes (N05C), antidepresivos (N06A) y agentes contra enfermedades obstructivas de las vías respiratorias (R03). Respecto al promedio europeo (100), el consumo español de estos grupos terapéuticos es: N02A, 37; C07, 40; B01AA, 41; C03, 70; N05C, 72; C10, 75; C08, 76; N05A, 77; J01, 97; N06A, 98; C09, 104; M01A, 101; R03, 101; C02, 107; A10, 114; N05B, 137; A02B, 150, y C04, 234. Conclusiones: El consumo español de la mayor parte de los grupos terapéuticos se encuentra muy cerca del promedio del grupo de países con el que ha sido posible compararlo o claramente por debajo del mismo, exceptuando el consumo de antiulcerosos, ansiolíticos y vasodilatadores periféricos que superan notablemente el promedio del grupo(AU)</dc:description>
<dc:source>Aten Primaria;44(6): 335-347, jun. 2012. graf, tab</dc:source>
<dc:identifier>ibc-101669</dc:identifier>
<dc:title xml:lang="es">Utilización de medicamentos en España y en Europa</dc:title>
<dc:subject>^d^s22045</dc:subject>
<dc:subject>^d30152^s22034</dc:subject>
<dc:subject>^d8059^s22048</dc:subject>
<dc:subject>^d30152^s22066</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d23106^s22000</dc:subject>
<dc:subject>^d23106^s22044</dc:subject>
<dc:subject>^d8059^s37748</dc:subject>
<dc:subject>^d4398^s22045</dc:subject>
<dc:subject>^d13411^s22080</dc:subject>
<dc:subject>^d8059^s22074</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d8059^s22083</dc:subject>
<dc:subject>^d22780</dc:subject>
<dc:subject>^d5158^s22080</dc:subject>
<dc:subject>^d30152^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201206</dc:date>
</metadata>
</record>
</ibecs-document>
